Clinical Trials Sponsored by Karin Palmblad

Total 361 results

Karin Palmblad
Karolinska Institutet

Unknown

NEMOS in Normal Volunteer and JIA Study

Inflammatory Response

Sweden
Kyowa Kirin, Inc.
Kyowa Kirin Co., Ltd.

Completed

Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH)

X-linked Hypophosphatemia

United States, Korea, Republic of, Japan, Ireland, United Kingdom, France, Italy
Kyowa Kirin, Inc.
Kyowa Kirin Co., Ltd.

Completed

Efficacy and Safety of Burosumab (KRN23) Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With X Linked Hypophosphatemia (XLH)

X-Linked Hypophosphatemia

Korea, Republic of, Canada, United States, Australia, Japan, United Kingdom, Sweden
Kyowa Kirin, Inc.
Kyowa Kirin Co., Ltd.

Completed

Study of KRN23 (Burosumab), a Recombinant Fully Human Monoclonal Antibody Against Fibroblast Growth Factor 23 (FGF23), in Pediatric Subjects With X-linked Hypophosphatemia (XLH)

X-linked Hypophosphatemia

Netherlands, United States, United Kingdom, France
Karin High
University of Kentucky

Terminated

Effect of Acetyl-L-carnitine on Chronic Pancreatitis

Chronic Pancreatitis

United States
Kyowa Kirin, Inc.
Kyowa Kirin Co., Ltd.

Completed

Open Label Study of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH)

X-linked Hypophosphatemia

United States, Korea, Republic of, Canada, Japan, France, Denmark
Kyowa Kirin, Inc.
Kyowa Kirin Co., Ltd.

Completed

Study of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderate to Severe Atopic Dermatitis

Atopic Dermatitis

United States, Canada, Germany, Japan
Karin Schindler

Completed

Infant Nutrition in Austria (Sukie)

Breast Feeding

Austria
Kyowa Hakko Kirin Pharma, Inc.

Terminated

Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Study of KW-2449 in Acute Myelogenous Leukemia (AML) (Protocol Number: 2449-US-002)

Acute Myelogenous Leukemia (AML)

United States
Kyowa Hakko Kirin Pharma, Inc.

Terminated

Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer

Colorectal Cancer

United States
Kyowa Hakko Kirin Pharma, Inc.

Terminated

Safety, Tolerability, and Efficacy Study in Subjects With Advanced or Metastatic Breast Cancer

Breast Cancer

United States
Kyowa Hakko Kirin Pharma, Inc.

Completed

A Study of KRN23 in X-linked Hypophosphatemia

X-linked Hypophosphatemia

United States
Kyowa Hakko Kirin Pharma, Inc.

Terminated

Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer

Neoplasms | Ovarian Neoplasms | Fallopian Tube Neoplasms | Primary Peritoneal Neoplasm

United States
Kyowa Hakko Kirin Pharma, Inc.

Completed

Safety Study to Evaluate KW-2450 in Subjects With Advanced Solid Tumor

Solid Tumor

United States
Kyowa Kirin, Inc.
Kyowa Kirin Co., Ltd.

Completed

Long-Term Extension Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH)

X-Linked Hypophosphatemia

United States
Kyowa Hakko Kirin Pharma, Inc.
Kyowa Kirin Co., Ltd.

Completed

An Extension Study of KRN23 in Adults With X-Linked Hypophosphatemia

X-linked Hypophosphatemia

United States, Canada
Kyowa Hakko Kirin Pharma, Inc.
Kyowa Kirin Co., Ltd.

Completed

A Study to Evaluate Abuse Potential of Istradefylline

Drug Abuse

United States
Kyowa Kirin, Inc.

Recruiting

Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema

Diabetic Macular Edema (DME)

United States, Japan, Korea, Republic of, Australia
Kyowa Kirin, Inc.

Active, not recruiting

Mogamulizumab Q4week Dosing in Participants With R/R CTCL

Cutaneous T-Cell Lymphoma Refractory | Cutaneous T-Cell Lymphoma, Relapsed

United States, United Kingdom, Spain, France, Italy
Kyowa Kirin, Inc.

Completed

Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL

Cutaneous T-Cell Lymphoma

United States, Spain, France, Australia, Switzerland, United Kingdom, Japan, Denmark, Germany, Italy, Netherlands
Kyowa Kirin, Inc.

Completed

Single-dose Study to Investigate the Plasma PK of KW-6356 and Its Major Metabolite

Hepatic Impairment

United States
Kyowa Kirin, Inc.

Completed

Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-KW-6356

Healthy Male Subjects

United States
Kyowa Kirin, Inc.

Completed

A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa

Parkinson's Disease

United States
Kyowa Hakko Kirin Pharma, Inc.
Kyowa Kirin Co., Ltd.

Completed

A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease (KW-6002)

Idiopathic Parkinson's Disease

United States, Canada, Czechia, Germany, Israel, Italy, Poland, Serbia
Kyowa Hakko Kirin Pharma, Inc.
Kyowa Kirin Co., Ltd.

Completed

A Repeated Study of KRN23 in Adults With X-Linked Hypophosphatemia

X-linked Hypophosphatemia

United States, Canada
Kyowa Hakko Kirin Pharma, Inc.
Kyowa Kirin Co., Ltd.

Completed

Long Term Study of Istradefylline in Subjects With Moderate to Severe Parkinson's Disease

Idiopathic Parkinson's Disease

United States, Canada, Czechia, Germany, Israel, Italy, Poland, Serbia
Kyowa Hakko Kirin Pharma, Inc.
Kyowa Kirin Co., Ltd.

Completed

A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma

United States, Philippines, United Kingdom
Kyowa Hakko Kirin UK, Ltd.

Completed

A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease

Parkinson's Disease

United Kingdom
Kyowa Hakko Kirin Pharma, Inc.

Terminated

Phase 1/2 Study of Anti GM-2 Monoclonal Antibody To Treat Multiple Myeloma

Multiple Myeloma

United States
Kyowa Hakko Kirin Pharma, Inc.

Completed

Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL)

Peripheral T-Cell Lymphoma

France, United Kingdom, Netherlands, Denmark, Italy, Spain
Kyowa Hakko Kirin UK, Ltd.

Completed

A Phase I Safety, PK and PD Study of KW-2478 in Patients With Multiple Myeloma, Chronic Lymphocytic Leukaemia or B-cell Non-Hodgkin's Lymphoma

Multiple Myeloma | Chronic Lymphocytic Leukaemia | B-cell Non-Hodgkin's Lymphoma

United Kingdom
Kyowa Kirin, Inc.

Recruiting

A Study of KK2269 in Adult Participants With Solid Tumors

Gastric Adenocarcinoma | Non Small Cell Lung Cancer | Advanced Solid Tumor | Metastatic Solid Tumor | Esophageal Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

Japan
Kyowa Kirin, Inc.

Recruiting

Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration

Neovascular Age-Related Macular Degeneration (nAMD)

United States, Japan, Korea, Republic of, Australia
Kyowa Kirin, Inc.

Recruiting

Post-authorization Safety Study of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Treated With Mogamulizumab

Cutaneous T Cell Lymphoma | ATLL | Leukemia/Lymphoma

United States
Kyowa Kirin, Inc.

Completed

A Long-Term, Safety Study With a Flexible Dose Range of KW-6002 in Patients With Motor Response Complications on Levodopa/Carbidopa Therapy

Parkinson's Disease

United States
Kyowa Kirin, Inc.

Completed

Study of Burosumab (KRN23) in Adults With Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS)

Tumor Induced Osteomalacia (TIO) | Epidermal Nevus Syndrome (ENS)

United States
Kyowa Kirin, Inc.

Completed

Study of the Safety, Pharmacodynamics (PD) and Efficacy of KRN23 in Children From 1 to 4 Years Old With X-linked Hypophosphatemia (XLH)

X-Linked Hypophosphatemia

United States
Kyowa Kirin, Inc.

Completed

Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis

Digestive System Diseases | Gastrointestinal Diseases | Colonic Diseases | Intestinal Diseases | Abdominal Pain | Inflammatory Bowel Diseases | Ulcerative Colitis | Colitis | Colitis, Ulcerative | Autoimmune Disease

Hungary, Russian Federation, Serbia, United States, Poland, Czechia, Romania
Kyowa Kirin, Inc.

Terminated

Study of KHK2823 in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United Kingdom
Kyowa Kirin, Inc.

Completed

Study of Mogamulizumab + Docetaxel in Subjects With Non-small Cell Lung Cancer

Non-Small Cell Lung Cancer

United States
Kyowa Kirin, Inc.

Completed

KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)

Adult T-cell Leukemia-Lymphoma

United States, United Kingdom, Belgium, France, Brazil, Peru
Kyowa Kirin, Inc.

Completed

A Study of Istradefylline (KW-6002) in Treating Patients With Parkinson's Disease on Levodopa

Parkinson's Disease

United States
Kyowa Kirin, Inc.

Completed

A Study of Istradefylline (KW-6002) as Monotherapy in Parkinson's Disease (PD) Patients

Parkinson's Disease | Movement Disorder Syndrome

United States
Kyowa Kirin, Inc.

Terminated

A Study of a Monoclonal Antibody, KW-2871, in Patients With Advanced Melanoma

Stage IV Melanoma

United States
Dr. Karin Hediger

Not yet recruiting

Dog Presence and Oxytocin on Trust Towards Therapists (DOT)

Depressive Symptoms | Human-Animal Interaction
Dr. Karin Hediger

Completed

Neurodynamic of the Human Brain Underlying Animal-assisted Intervention in Healthy Adults (NMAAI)

Animal-assisted Intervention

Switzerland
Kyowa Hakko Kirin Pharma, Inc.

Completed

Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell Lymphoma

Peripheral T-Cell Lymphoma

United States
Kyowa Hakko Kirin Pharma, Inc.

Completed

Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001

Cutaneous T-cell Lymphoma | Peripheral T-cell Lymphoma

United States
Kyowa Hakko Kirin Pharma, Inc.

Completed

A Study of Single and Multiple Doses of KHK6640 in Subjects With Prodromal or Mild to Moderate Alzheimer's Disease

Alzheimer's Disease

Belgium, Finland, Netherlands, Serbia, Sweden
Kyowa Kirin, Inc.
Kyowa Hakko Kirin UK, Ltd.

Completed

An Extension of Istradefylline in Parkinson's Disease Patients Who Have Completed Studies 6002-EU-007, 6002-US-013 or 6002-US-018

Parkinson's Disease

United States

Clinical Trials Sponsored by Karin Palmblad

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ethiopia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations